Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PfAMA1-FVO
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PfAMA1-FVO is a recombinant protein vaccine candidate designed to prevent *Plasmodium falciparum* malaria. It consists of the ectodomain (amino acids 25–545) of the Apical Membrane Antigen 1 (AMA1) derived from the FVO (Falcetti/Vietnam/Oak Knoll) strain of the parasite. Expressed in the yeast *Pichia pastoris*, the protein is typically formulated with an adjuvant such as Alhydrogel. AMA1 is a microneme protein essential for the invasion of host erythrocytes; it interacts with Rhoptry Neck Protein 2 (RON2) to facilitate the formation of a moving junction during parasite entry. The vaccine aims to induce high titers of neutralizing antibodies that block this interaction, thereby inhibiting the parasite's life cycle at the blood stage.
- Other names
- AMA1-FVOAMA-1-FVOAMA 1-FVOPlasmodium falciparum apical membrane antigen 1 FVO strainrecombinant PfAMA1-FVO
02
Targets
AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on PfAMA1-FVO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PfAMA1-FVO.